G1 Therapeutics (GTHX) Earnings Date, Estimates & Call Transcripts $7.15 0.00 (0.00%) (As of 09/18/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 6EstimatedActual EPS (Aug. 8) -$0.10 Beat By $0.07 Consensus EPS (Aug. 8) -$0.17 Get G1 Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for GTHX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueGTHX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.GTHX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). G1 Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.20)($0.20)($0.20)Q2 20242($0.18)($0.18)($0.18)Q3 20242($0.17)($0.06)($0.12)Q4 20242($0.02)($0.01)($0.02)FY 20248($0.57)($0.45)($0.51)Q1 20251($0.01)($0.01)($0.01)Q2 20251$0.00$0.00$0.00Q3 20251$0.00$0.00$0.00Q4 20251$0.00$0.00$0.00FY 20254($0.01)($0.01)($0.01)GTHX Earnings Date and InformationG1 Therapeutics last issued its earnings data on August 8th, 2024. The reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.07. The business earned $16.55 million during the quarter, compared to the consensus estimate of $15.88 million. G1 Therapeutics has generated ($0.62) earnings per share over the last year (($0.62) diluted earnings per share). Earnings for G1 Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.12) per share. G1 Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off prior year's report dates.Read More G1 Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/6/2024(Estimated)------- 8/8/2024Q2 2024($0.17)($0.10)+$0.07($0.10)$15.88 million$16.55 million5/1/2024Q1 2024($0.19)($0.20)($0.01)($0.20)$15.21 million$14.48 million 2/28/2024Q4 2023($0.27)($0.21)+$0.06($0.21)$12.83 million$14.87 million 11/1/2023Q3 2023($0.31)($0.35)($0.04)($0.35)$13.73 million$12.30 million 8/2/2023Q2 2023($0.17)$0.14+$0.31$0.14$28.34 million$42.39 million 5/3/2023Q1 2023($0.64)($0.53)+$0.11($0.53)$10.54 million$12.95 million Get the Latest News and Ratings for GTHX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/1/2023Q4 2022($0.85)($0.73)+$0.12($0.73)$9.61 million$10.25 million 11/2/2022Q3 2022($0.64)($0.59)+$0.05($0.59)$22.64 million$23.58 million 8/3/2022Q2 2022($1.04)($0.92)+$0.12($0.92)$9.00 million$10.57 million 5/4/2022Q1 2022($0.99)($1.15)($0.16)($1.15)$5.78 million$6.90 million 2/23/2022Q4 2021($1.03)($0.94)+$0.09($0.94)$5.45 million$5.80 million 11/3/2021Q3 2021($1.03)($1.00)+$0.03($1.00)$4.31 million$4.86 million 8/4/2021Q2 2021($0.96)($0.94)+$0.02($0.94)$2.70 million$6.60 million 5/5/2021Q1 2021($1.09)($0.65)+$0.44($0.65)$0.37 million$14.22 million 2/24/2021Q4 2020($0.88)($0.67)+$0.21($0.67)$14.00 million$16.55 million 11/4/2020Q3 2020($0.25)($0.31)($0.06)($0.31)$40.00 million$26.60 million 8/5/2020Q2 2020($0.83)($0.83)-($0.83)$6.00 million$2.14 million 5/6/2020Q1 2020($0.98)($0.82)+$0.16($0.82)-- 2/26/2020Q4($0.96)($0.94)+$0.02($0.94)-- 11/5/2019Q3($0.87)($0.86)+$0.01($0.86)-- G1 Therapeutics Earnings - Frequently Asked Questions When is G1 Therapeutics's earnings date? G1 Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates. Learn more on GTHX's earnings history. Did G1 Therapeutics beat their earnings estimates last quarter? In the previous quarter, G1 Therapeutics (NASDAQ:GTHX) reported ($0.10) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.17) by $0.07. Learn more on analysts' earnings estimate vs. GTHX's actual earnings. How much revenue does G1 Therapeutics generate each year? G1 Therapeutics (NASDAQ:GTHX) has a recorded annual revenue of $58.20 million. How much profit does G1 Therapeutics generate each year? G1 Therapeutics (NASDAQ:GTHX) has a recorded net income of -$47.97 million. GTHX has generated -$0.62 earnings per share over the last four quarters. What is G1 Therapeutics's EPS forecast for next year? G1 Therapeutics's earnings are expected to grow from ($0.45) per share to ($0.12) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Rigel Pharmaceuticals Earnings Results Dynavax Technologies Earnings Results NewAmsterdam Pharma Earnings Results Disc Medicine Earnings Results Avadel Pharmaceuticals Earnings Results Longboard Pharmaceuticals Earnings Results Ardelyx Earnings Results Ocular Therapeutix Earnings Results Cassava Sciences Earnings Results Bicycle Therapeutics Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings This page (NASDAQ:GTHX) was last updated on 9/18/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | SponsoredThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share G1 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
